Fri, Dec 19, 2014, 5:43 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Medivation, Inc. (MDVN) Message Board

  • dickeymellon dickeymellon Jun 25, 2013 4:55 PM Flag

    J&J aquisition, ARGN destroys MDVN's Xtandi in trials

    In an interview the inventor, Dr Charles Sawyers noted that ARN-509 is "more potent" than Xtandi and "might produce a higher percentage of responders or a longer duration of response." Also, ARN-509 will allow J&J to compete in earlier stages of prostate cancer with a drug that does not require the use of steroids, which has been a problem for Zytiga in treating pre-chemotherapy patients.

    Competition over pricing might also arise. At a cost of $7,450 a month, Xtandi is considerably more expensive than Zytiga, which costs around $5,500 per month. This aggressive premium pricing strategy opens the door to competitors, such as ARN-509, who may offer equally effective, but less expensive drugs.

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
108.34-0.83(-0.76%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.